New Tyrosine Kinase Inhibitors Data Have Been Reported by Investigators at University of Brescia (The Italian Multicentric Randomized Optkima Trial On Fixed Vs Progressive Intermittent Tki Therapy In Cml Elderly Patients: 3-tears of Molecular...).

A recent study conducted at the University of Brescia in Italy explored the use of tyrosine kinase inhibitors (TKIs) as a treatment option for elderly patients with chronic myeloid leukemia (CML). The study compared two different schedules of TKI therapy: a fixed schedule and a progressive intermittent schedule. The findings showed that both schedules were safe and feasible, with the progressive intermittent schedule associated with a higher incidence of molecular remission loss. Health-related quality of life improved during both schedules, and the progressive schedule was considered a valid tool for selecting patients eligible for TKI discontinuation. Overall, the study found that the quality of life generally improved during the de-escalation therapy in both arms of the study. [Extracted from the article]